News

Stop TB Partnership Craig David Video Series #3

In a newly released clip – the third in a series of videos shot in South Africa during his first country visit as a Goodwill Ambassador against Tuberculosis – British R&B star Craig David talks with Dr Sizulu Moyo, a tuberculosis researcher at Stellenbosch University.

Dr Sizulu Moyo

Dr Sizulu Moyo

Against the backdrop of a busy research laboratory, Craig learns that lots of progress has been made and momentum gained in the diagnosis and treatment of tuberculosis thanks to collaboration among partners as well as increased awareness and commitment from poor and rich countries alike, spurred by the link between tuberculosis and HIV/AIDS: tuberculosis is the leading infectious killer of people living with HIV.

Two key challenges mentioned by Dr Moyo are the need for sufficient funding to develop an effective vaccine and the need for tuberculosis patients to complete their course of treatment (which lasts 6 months or more) to keep the medicines effective: incomplete treatment will lead to the tuberculosis bacteria becoming drug-resistant. While people are aware that they should finish treatment, she explains, “it’s a complicated scenario; there are many things that come into play…We need understand where they are coming from. They are people with lives, with families.”

Despite her laboratory surroundings Dr Moyo remains very aware of the real-life implications of her research: “It’s not only about the documents that you read, any nice brochures, it’s not about the presentations that you make… TB affects real people, real families and real communities.”

More News
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...
21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
12 Mar 2019
On March 8th, TB Alliance announced its novel compound, Pretomanid, is currently being reviewed by the FDA for use against Tuberculosis. TB Alliance's press release can be found below: NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug...